123 related articles for article (PubMed ID: 37607620)
1. Comparative analysis of YAP/TEAD inhibitors in 2D and 3D cultures of primary human hepatocytes reveals a novel non-canonical mechanism of CYP induction.
Oliva-Vilarnau N; Vorrink SU; Büttner FA; Heinrich T; Sensbach J; Koscielski I; Wienke D; Petersson C; Perrin D; Lauschke VM
Biochem Pharmacol; 2023 Sep; 215():115755. PubMed ID: 37607620
[TBL] [Abstract][Full Text] [Related]
2. Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes.
Hendriks DFG; Vorrink SU; Smutny T; Sim SC; Nordling Å; Ullah S; Kumondai M; Jones BC; Johansson I; Andersson TB; Lauschke VM; Ingelman-Sundberg M
Clin Pharmacol Ther; 2020 Oct; 108(4):844-855. PubMed ID: 32320483
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
Elife; 2022 Nov; 11():. PubMed ID: 36398861
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail.
Berger B; Donzelli M; Maseneni S; Boess F; Roth A; Krähenbühl S; Haschke M
Front Pharmacol; 2016; 7():443. PubMed ID: 27917125
[TBL] [Abstract][Full Text] [Related]
5. Role of YAP Activation in Nuclear Receptor CAR-Mediated Proliferation of Mouse Hepatocytes.
Abe T; Amaike Y; Shizu R; Takahashi M; Kano M; Hosaka T; Sasaki T; Kodama S; Matsuzawa A; Yoshinari K
Toxicol Sci; 2018 Oct; 165(2):408-419. PubMed ID: 29893953
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 induction response in tethered spheroids as a three-dimensional human hepatocyte in vitro model.
Xia L; Hong X; Sakban RB; Qu Y; Singh NH; McMillian M; Dallas S; Silva J; Sensenhauser C; Zhao S; Lim HK; Yu H
J Appl Toxicol; 2016 Feb; 36(2):320-9. PubMed ID: 26201057
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of YAP/TAZ-TEAD activity induces cytotrophoblast differentiation into syncytiotrophoblast in human trophoblast.
Mizutani T; Orisaka M; Miyazaki Y; Morichika R; Uesaka M; Miyamoto K; Yoshida Y
Mol Hum Reprod; 2022 Sep; 28(10):. PubMed ID: 35993908
[TBL] [Abstract][Full Text] [Related]
8. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
9. Prediction of cytochrome 450 mediated drug-drug interactions by three-dimensional cultured hepatocytes.
Shen C; Meng Q
Mini Rev Med Chem; 2012 Sep; 12(10):1028-36. PubMed ID: 22512564
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction.
Li AP; Maurel P; Gomez-Lechon MJ; Cheng LC; Jurima-Romet M
Chem Biol Interact; 1997 Nov; 107(1-2):5-16. PubMed ID: 9402946
[TBL] [Abstract][Full Text] [Related]
11. Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
Wang M; Yan Q; Song Y; Zhang Z; Chen X; Gao K; Wan X
Oncogene; 2023 Jan; 42(4):322-334. PubMed ID: 36446891
[TBL] [Abstract][Full Text] [Related]
12. CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis.
Guo Y; Zhu Z; Huang Z; Cui L; Yu W; Hong W; Zhou Z; Du P; Liu CY
Nat Commun; 2022 Aug; 13(1):4995. PubMed ID: 36008411
[TBL] [Abstract][Full Text] [Related]
13. TEAD mediates YAP-dependent gene induction and growth control.
Zhao B; Ye X; Yu J; Li L; Li W; Li S; Yu J; Lin JD; Wang CY; Chinnaiyan AM; Lai ZC; Guan KL
Genes Dev; 2008 Jul; 22(14):1962-71. PubMed ID: 18579750
[TBL] [Abstract][Full Text] [Related]
14. Functional Interaction between Pregnane X Receptor and Yes-Associated Protein in Xenobiotic-Dependent Liver Hypertrophy and Drug Metabolism.
Abe T; Shizu R; Sasaki T; Shimizu Y; Hosaka T; Kodama S; Matsuzawa A; Yoshinari K
J Pharmacol Exp Ther; 2019 Dec; 371(3):590-601. PubMed ID: 31533970
[TBL] [Abstract][Full Text] [Related]
15. Identification of Small-molecule YAP-TEAD inhibitors by High-throughput docking for the Treatment of colorectal cancer.
Li L; Li R; Wang Y
Bioorg Chem; 2022 May; 122():105707. PubMed ID: 35247806
[TBL] [Abstract][Full Text] [Related]
16. YAP-TEAD up-regulates IRS2 expression to induce and deteriorate oesophageal cancer.
Xu X; Nie J; Lu L; Du C; Meng F; Song D
J Cell Mol Med; 2021 Mar; 25(5):2584-2595. PubMed ID: 33570213
[TBL] [Abstract][Full Text] [Related]
17. Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics.
Foster CT; Gualdrini F; Treisman R
Genes Dev; 2017 Dec; 31(23-24):2361-2375. PubMed ID: 29317486
[TBL] [Abstract][Full Text] [Related]
18. Blockage of glioma cell survival by truncated TEAD-binding domain of YAP.
Zhao W; Dong QF; Li LW; Yan ZF; Huo JL; Chen XY; Yang X; Li PQ; Fei Z; Zhen HN
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1713-1723. PubMed ID: 33651140
[TBL] [Abstract][Full Text] [Related]
19. The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition.
Furet P; Bordas V; Le Douget M; Salem B; Mesrouze Y; Imbach-Weese P; Sellner H; Voegtle M; Soldermann N; Chapeau E; Wartmann M; Scheufler C; Fernandez C; Kallen J; Guagnano V; Chène P; Schmelzle T
ChemMedChem; 2022 Oct; 17(19):e202200303. PubMed ID: 35950546
[TBL] [Abstract][Full Text] [Related]
20. The fibrotic response of primary liver spheroids recapitulates in vivo hepatic stellate cell activation.
Mannaerts I; Eysackers N; Anne van Os E; Verhulst S; Roosens T; Smout A; Hierlemann A; Frey O; Leite SB; van Grunsven LA
Biomaterials; 2020 Dec; 261():120335. PubMed ID: 32891040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
